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        Melioidosis is a community-acquired infectious disease 
caused by the Gram-negative bacillus   Burkholderia pseudo-
mallei . 1   This organism is present in the environment in areas 
where melioidosis is endemic, and infection is acquired 
through skin inoculation, inhalation or ingestion. Melioidosis 
is the most common cause of community-acquired bacteremic 
pneumonia in northern Australia  2   and the third most frequent 
cause of death from infection diseases in northeastern Thailand 
(after human immunodeficiency virus/acquired immunodefi-
ciency syndrome and tuberculosis).  1   Common manifestations 
include pneumonia, hepatosplenic abscesses, septic arthritis, 
parotid and prostatic abscesses, and urinary tract infection. 
Persons with suspected melioidosis require hospital admission 
cultures of blood, respiratory secretions, urine, throat swab, 
pus if abscesses are identified and accessible, and swabs from 
any skin lesions.   Burkholderia pseudomallei   is not part of the 
normal human flora, and isolation of this organism from any 
specimen is diagnostic for melioidosis. 
  Death occurs in 40% of patients with melioidosis in our 
setting.  1   Several factors have been identified that are associ-
ated with a higher risk of death, including older age, pneumo-
nia, markers of organ dysfunction, positive blood culture, and 
high quantitative count of   B. pseudomallei   in blood or urine.  3  ,  4  
Follow-up cultures are easy to perform and relatively inex-
pensive, but there is limited information on the significance of 
positive   B. pseudomallei   cultures over time and whether these 
provide additional prognostic information. We evaluated the 
hypothesis that follow-up qualitative and/or quantitative cul-
ture can be used to predict survival outcome in patients with 
melioidosis. 
  The patients described here were consecutive individuals 
presenting to Sappasithiprasong Hospital between January 1, 
1997 and December 31, 2006 with culture-confirmed melioido-
sis who were identified as part of on-going surveillance associ-
ated with clinical trials. The hospital diagnostic laboratory was 
contacted daily to identify patients with one or more cultures 
positive for   B. pseudomallei  . Rounds of the medical and inten-
sive care wards were conducted daily to identify additional 
cases. Any patient not already known to us who we suspected 
of having melioidosis on the basis of admission clinical fea-
tures had samples obtained for culture, including blood, respi-
ratory secretions (sputum, or tracheal aspirate if intubated), 
urine, throat swab, pus, and surface swabs from skin lesions. 
  Microbiologic specimens were processed as described pre-
viously.  5   All patients with microbiologically confirmed melioi-
dosis were subsequently visited daily to obtain information 
on history, examination findings, and outcome (defined as 
survival to discharge or in-hospital death). Repeat blood cul-
ture was performed at the end of the first and second weeks 
after diagnosis in patients who were failing to improve despite 
parenteral antimicrobial therapy. In addition, other specimen 
types that were positive for   B. pseudomallei   at admission were 
obtained every week until negative results were obtained, and 
patients in whom new signs and symptoms developed and were 
suspected of new organ involvement had a repeat screening of 
relevant clinical specimens. 
  For purposes of analysis, clinical specimens obtained within 
the first three days were grouped as admission samples, those 
obtained during days 4–10 as first follow-up samples, and those 
obtained after day 10 as second follow-up samples. A few rela-
tives took moribund patients home to die and these patients 
were assumed to have died. 
  Ethical approval for all clinical trials was obtained from the 
Ethical and Scientific Review Subcommittee of Thai Ministry 
of Public Health.  6–  9   Quantitative culture of blood, urine, spu-
tum, and pus was performed in adult patients (> 18 years of 
age) during 2004–2006 as described.  10  
  Simple and multivariable logistic regression analysis was 
used to examine the association between culture result and 
outcome. Sex, age, history of diabetes, pneumonia, hypoten-
sion, and duration of in-hospital intravenous antimicrobial 
treatment received were included in the multivariable analy-
sis. Drugs used were amoxicillin/clavulanate, ceftazidime, and 
carbapenems. Fisher’s exact test and the Mann-Whitney test 
were used to compare categorical variables and continuous 
variable between groups, respectively. 
  There were 2,243 patients admitted to Sappasithipra-
song  Hospital during 1997–2006 with their first episode of 
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culture-confirmed melioidosis. Of these patients, 1,314 (59%) 
were male and 929 (41%) were female. Median age was 49 
years (interquartile range [IQR] = 37–60 years), and 212 
patients (9%) were less than 15 years of age. Death occurred 
in 956 patients (43%). 
  On admission, blood, respiratory secretions, urine, throat 
swab, and pus/surface swab were obtained for culture from 
1,997, 841, 1,152, 874, and 862 patients, respectively (  Table 1  ). 
Of these patients, blood, respiratory secretions, urine, throat 
swab, and pus/surface swab culture were positive for  B. pseudo-
mallei   in 1,160 (58%), 550 (65%), 255 (22%), 324 (37%) and 
761 (85%) patients, respectively. Having a blood, respiratory 
secretion, urine, or throat swab culture obtained on admis-
sion that was positive for   B. pseudomallei   was strongly asso-
ciated with death (  P   ≤ 0.01, for all specimens) (  Table 1  ). 
Having a pus/surface swab culture obtained on admission 
that was positive for   B. pseudomallei   was associated with a 
survival outcome, and most of these patients (58%, 443 of 
761 patients) had only one localized lesion. Associations 
between death and a   B. pseudomallei -positive  respiratory 
secretion, urine, or throat swab culture on admission was 
independent of bacteremia (  Table 2  ). 
 Table 1 
    Prognostic value of a positive culture of blood, respiratory secretion, urine, throat swab, and pus/surface swab culture on admission, first follow-up 
sampling period (4–10 days after admission), and second follow-up sampling period (after day 10) in patients with melioidosis, Thailand *   
Sample type and timing
No. patients who died/total no. patients, 
(% mortality rate) Crude OR (95% CI) Adjusted OR  †   (95% CI)   P  ‡  
Blood
 At  hospitalization
    Positive 733/1,160 (63.2) 7.0 (5.7–8.7) 5.1 (4.0–6.6) < 0.001
  Negative 164/837  (19.6)
  During first follow-up sampling period
    Positive 25/66 (37.9) 3.6 (2.0–6.6) 4.2 (2.1–8.7) < 0.001
  Negative 37/255  (14.5)
  During second follow-up sampling period
    Positive 18/37 (48.7) 3.1 (1.5–6.5) 2.6 (1.1–6.0) 0.03
  Negative 36/153  (23.5)
Respiratory secretion
 At  hospitalization
    Positive 284/550 (51.6) 1.8 (1.4–2.5) 1.8 (1.1–2.8) 0.01
  Negative 107/291  (36.8)
  During first follow-up sampling period
    Positive 11/69 (15.9) 0.6 (0.2–1.5) 0.4 (0.1–1.5) > 0.1
  Negative 9/36  (25.0)
  During second follow-up sampling period
    Positive 9/35 (25.7) 1.7 (0.5–5.3) 4.9 (0.8–31) 0.09
  Negative 6/35  (17.1)
Urine
 At  hospitalization
    Positive 147/255 (57.7) 2.9 (2.2–3.9) 2.1 (1.5–3.0) < 0.001
  Negative 284/897  (31.7)
  During first follow-up sampling period
    Positive 4/16 (25.0) 1.0 (0.3–3.5) 1.9 (0.4–8.3) > 0.1
  Negative 26/107  (24.3)
  During second follow-up sampling period
    Positive 1/6 (16.7) 0.6 (0.1–5.5) 0.3 (0.0–5.8) > 0.1
  Negative 12/47  (25.5)
Throat swab
 At  hospitalization
    Positive 127/324 (39.2) 3.7 (2.7–5.2) 3.1 (2.0–4.8) < 0.001
  Negative 81/550  (14.7)
  During first follow-up sampling period
    Positive 3/23 (13.0) 1.1 (0.2–4.9) 1.1 (0.2–7.1) > 0.1
  Negative 5/40  (12.5)
  During second follow-up sampling period
    Positive 3/11 (27.3) 7.1 (1.0–49.8) 21 (0.5–871) > 0.1
  Negative 2/40  (5.0)
Pus/surface swab
 At  hospitalization
    Positive 130/761 (17.1) 0.5 (0.3–0.8) 0.5 (0.3–0.9) 0.01
  Negative 37/131  (28.2)
  During first follow-up sampling period
    Positive 18/114 (15.8) 2.1 (0.7–6.5) 1.5 (0.4–5.5) > 0.1
  Negative 4/48  (8.3)
  During second follow-up sampling period
    Positive 12/92 (13.0) 4.8 (0.6–38.5) 6.7 (0.7–60) 0.09
  Negative 1/33  (3.0)
    *     OR = odds ratio; CI = confidence interval; Positive = positive for   Burkholderia pseudomallei  ; Negative = negative for   B. pseudomallei.   
    †     OR was adjusted for blood culture positive for   B .   pseudomallei  , sex, age, history of diabetes, pneumonia, hypotension, and duration of in-hospital intravenous antimicrobial treatment received.  
  ‡     P   value for adjusted OR.   860 LIMMATHUROTSAKUL AND OTHERS
           Follow-up  blood  cultures  were  performed  during  days  4–10 
in 321 patients and after day 10 in 190 patients. Patients who 
had a blood culture positive for   B. pseudomallei   on admission 
were more likely to have a positive follow-up blood culture 
than patients who had a negative admission blood culture 
(31% [50 of 159] versus 10% [16 of 162];  P  < 0.001). The median 
duration of antimicrobial drugs received in patients who had 
a positive follow-up blood culture was not different from that 
of patients who had a negative follow-up blood culture (7 days 
[IQR = 5–7 days] versus 7 days [IQR = 4–7 days];   P   > 0.1). 
Multivariable logistic regression demonstrated that follow-up 
blood cultures positive for   B. pseudomallei   were strongly asso-
ciated with death (adjusted odds ratio = 4.2, 95% confidence 
interval = 2.1–8.7,   P   < 0.001 and adjusted odds ratio = 2.6, 95% 
confidence interval = 1.1–6.0,   P   = 0.03, respectively). However, 
this association was not observed in follow-up culture of other 
specimen types (  Table 1  ). 
  The prognostic value of follow-up blood culture was evalu-
ated further in a subset of patients who had quantitative blood 
culture. Thirteen patients had quantitative blood culture on 
admission and one or more follow-up cultures (  Figure 1  ). All 
13 patients received ceftazidime or a carbapenem drug within 
the first two days after admission, and a decrease in bacterial 
count in blood was observed in all patients. Most patients with 
a positive quantitative follow-up blood culture (80%, 4 of 5 
patients) had an admission bacterial count in blood greater 
than 1 colony-forming unit (CFU)/mL, and most patients with 
a negative quantitative follow-up blood culture (88%, 7 of 8 
patients) had an admission bacterial count in blood of less 
than 1 CFU/mL (  P   = 0.03). Of these 13 patients, two patients 
who had a bacterial count in blood ≤ 100 CFU/mL at admis-
sion (patients A and B), and one patient who had persistent 
bacteremia (0.2 CFU/mL on day 2, 0.1 CFU/mL on day 17, and 
0.1 CFU/mL on day 26; patient D) died (  Figure 1  ). Patient D 
was a 66-year old man with diabetes mellitus and non-Hodgkin 
lymphoma, and was post-chemotherapy. The patient who had 
a follow-up blood culture of 4.7 CFU/mL on day 9 (patient C) 
improved and was transferred to continue parenteral therapy 
at a community hospital. 
    Our study shows that follow-up blood culture is an impor-
tant predictor of late in-patient death from melioidosis. This 
finding agrees with observations for other infectious dis-
eases.  11  ,  12   Response to antimicrobial therapy for melioidosis is 
often slow (mean duration of fever of 9 days),  13   and markers 
for patients who survive the first week of in-patient care but 
remain at risk of death are not well established. Our study 
indicates that patients with melioidosis should receive weekly 
follow-up blood culture until clearance of the organism from 
blood 
  Our results from a small subset of patients who had follow-
up quantitative blood culture indicated that positive follow-
up blood culture was associated with several factors, including 
high bacterial load on admission and an immunocompromise 
condition associated with a presumed failure to eradicate the 
infecting bacterium. We found that most of the patients who 
had follow-up positive blood culture had a bacterial count in 
blood of more than 1 CFU/mL on admission. However, one 
patient who had a bacterial count in blood of 0.2 CFU/mL 
failed to clear the organism from the blood (patient D). This 
finding could have been caused by his markedly impaired 
immune function and defective phagocytic cell function asso-
ciated with chemotherapy. This finding emphasizes that in the 
clinical setting, intensive and detailed management is required 
of patients with positive follow-up blood culture, even without 
data on quantitative count. 
  Although a positive culture of respiratory secretions, urine, 
or sputum on admission was associated with death, this asso-
ciation was not observed for follow-up cultures of these speci-
men types. Positive cultures of respiratory secretions and urine 
on admission represent organ involvement, including pneu-
monia and urinary tract infection, which have been shown to 
be independent prognostic factors for death.  3  
  This study extends previous findings by describing the 
value of a throat swab on admission as a prognostic factor, an 
observation that was independent of blood and urine culture 
results (as demonstrated by multivariable logistic regression). 
Furthermore, a throat swab is better than a sputum culture 
because it can be performed in every patient and not only 
patients with respiratory symptoms and sputum production. 
 Table 2 
    Prognostic significance of a respiratory secretion, urine, throat swab, 
and pus/surface swab culture positive for   Burkholderia pseudo-
mallei   on admission, adjusted for blood culture positive for 








Adjusted  OR †  
(95% CI)   P  ‡  
Positive respira-
tory secretions
224/386 (58.0) 276/393 (70.2) 2.3 (1.4–3.7) 0.001
Positive urine 152/564 (27.0) 82/545 (15.1) 1.9 (1.3–2.7) 0.001
Positive 
throat swab
149/361 (41.3) 171/497 (34.4) 3.1 (2.0–4.9) < 0.001
Positive pus/
surface swab
205/257 (79.8) 392/462 (84.9) 0.7 (0.4–1.2) > 0.1
    *      OR = odds ratio; CI = confidence interval; Positive = positive for   B .   pseudomallei ; 
Negative = negative for   B .   pseudomallei.   
    †     OR was adjusted for blood culture positive for   B .   pseudomallei  , sex, age, history of dia-
betes, pneumonia, hypotension, and duration of in-hospital intravenous antimicrobial treat-
ment received.   
  ‡     P   value for adjusted OR.   
 Figure  1.     Quantitative   Burkholderia pseudomallei   count in blood 
specimens obtained from 13 patients who had follow-up quantita-
tive hemoculture performed. Each line represents the results of one 
patient. Solid lines represent five patients who had follow-up hemocul-
ture positive for   B. pseudomallei   (patients A–E), and broken lines 
represent eight patients who had follow-up hemoculture negative for 
  B. pseudomallei  . Of 13 patients, three patients (A, B, and D) died. 
Patient C improved and was transferred to continue parenteral anti-
microbial therapy at a community hospital. Patient E had a positive 
follow-up blood culture of 0.1 colony-forming units/mL on day 16, but 
negative blood cultures on days 19 and 28.       861 PREDICTING MORTALITY FOR MELIOIDOSIS
Lack of an association between death and persistently pos-
itive respiratory secretions, urine, throat swab, and pus/sur-
face swab is new evidence supporting previous observations.  14  
This finding adds to our experience that a small number of 
patients with persistent culture of these specimens can none-
theless be cured with oral eradicative treatment.  14   Localized 
lesions are difficult to eradicate and slow to resolve, but rou-
tine follow-up culture of the related sample types does not 
appear to have any clinical utility. 
  A limitation of this study is that not all clinical specimens 
were obtained from every patient. For example, there were 
only 779 patients with respiratory symptoms who had respi-
ratory secretions and blood obtained for culture at admission 
(  Table 2  ). In addition, follow-up cultures were not performed 
in every patient, and the timing of repeat cultures was variable. 
Nonetheless, these limitations do not affect the main conclu-
sion of this study that blood culture should be followed up at 
least weekly in melioidosis patients and until a negative result 
is observed. 
  Received October 31, 2010. Accepted for publication February 6, 
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